Health

Results: 7009-7020 of 9382

Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

Stallergenes Greer Foundation Announces Winners of 2023 Science Awards for Allergy

Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing

Matt and Emma Willis, with Maxine and Darcy Laceby complete Absolute Collagen’s ‘Map My Baps’ challenge, a 21km trek through the Chilterns to drive awareness and support for breast cancer charity, Coppafeel. Issue date: Sunday May 26, 2024. PA Photo. The half marathon route took the shape of a pair of breasts. Photo credit should read: Anthony Upton/PA Media Assignments

ABSOLUTE COLLAGEN MAPS WORLD’S BIGGEST BREASTS AS PART OF ‘MAP MY BAPS’ 21K CHARITY TREK WITH CELEB FRIENDS

Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress

61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

PR Newswire associated0

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

Celltrion receives European Commission approval of Omlyclo® (CT-P39), the first and only omalizumab biosimilar approved in Europe

ONCOCLÍNICAS APPROVES R$ 1.5 BILLION CAPITAL INCREASE

Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting